Acute myeloid leukemia with TP53 mutation
Conditions
Interventions
Observation group:None
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients diagnosed with AML according to WHO 5th edition or ICC criteria, including de novo AML, secondary AML, or therapy-related AML; 2.Availability of bone marrow or peripheral blood samples suitable for NGS analysis at diagnosis, prior to initial treatment, or at a predefined baseline time point; 3.Detection of at least one TP53 mutation that can be definitively classified following basic quality control; 4.Availability of traceable clinical baseline data and follow-up outcomes; 5.For analyses of CR, complete data sufficient to assess treatment response must be available.
Exclusion criteria
Exclusion criteria: 1.Lack of a confirmable baseline sample; 2.Sequencing quality insufficient to determine TP53 status; 3.Missing key outcome information.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission;Overall survival;Variant allele frequency;Model differentiation;AUC;Brier score ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Bone marrow blast percentage;Hemoglobin;Absolute neutrophil count;Mutation type;Exon / mutation location;Co-mutation;Platelet count; | — |
Countries
China
Contacts
Public ContactSongfu Jiang
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed